Xeltis makes first commercial implant of aXess™, its vascular access device for hemodialysis

Marks start of European commercial rollout of aXess™, bringing it into routine clinical practiceBuilds on CE mark approval in ...

300 surgeries over 5 years

HUNDREDS of patients living with chronic kidney disease across southern Jamaica have gained improved access to haemodialysis ...

Hundreds of renal patients benefit as Mandeville hospital achieves milestone fistula procedures

Hundreds of patients living with chronic kidney disease across southern Jamaica gained improved access to haemodialysis ...
Healio

Suboptimal dialysis starts may lower odds for transplant referral, evaluation

Suboptimal dialysis starts may be associated with lower odds for transplant referral, evaluation and wait-listings, according ...

Dr. Mohana Rao Patibandla Delivers Stereotactic Radiosurgery Invited Lecture At YNFCON 2026 Mumbai

Dr. Mohana Rao Patibandla Delivers Stereotactic Radiosurgery Invited Lecture At YNFCON 2026 Mumbai. EINPresswire/ -- Founder of Dr. Rao's Hospital Highlights Essential SRS Principles for the Next ...

Humacyte's Bioengineered Blood Vessel Outperforms the Standard of Care for Women on Dialysis in Phase 3 Results Presented at the Society for Vascular Surgery Vascular Annual ...

Positive results from the V012 Phase 3 study were presented at the Society for Vascular Surgery's Vascular Annual Meeting in Boston – – Women who received Humacyte's ATEV ...
manilatimes

Humacyte ATEV Met Superiority Primary Endpoint Compared to Standard of Care AV Fistula in Interim Analysis of V012 Phase 3 Study in Female Dialysis Access Patients

- Humacyte plans to file a supplemental Biologic License Application (BLA) with the Food and Drug Administration (FDA) during the second half of 2026 - - The ATEV met V012’s primary endpoint and was ...
Mena FN

Humacyte ATEV Met Superiority Primary Endpoint Compared To Standard Of Care AV Fistula In Interim Analysis Of V012 Phase 3 Study In Female Dialysis Access Patients

(MENAFN- GlobeNewsWire - Nasdaq) - Humacyte plans to file a supplemental Biologic License Application (BLA) with the Food and Drug Administration (FDA) during the second half of 2026 - - The ATEV met ...